Harvard Apparatus Regenerative Technology Inc. (HRGN)
| Market Cap | 45.35M |
| Revenue (ttm) | 235.00K |
| Net Income (ttm) | -8.21M |
| Shares Out | 15.92M |
| EPS (ttm) | -0.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,900 |
| Open | 2.780 |
| Previous Close | 2.750 |
| Day's Range | 2.700 - 2.990 |
| 52-Week Range | 2.130 - 5.900 |
| Beta | -1.22 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 24, 2025 |
About HRGN
Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. The company’s pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy, birth defects, and r... [Read more]
Financial Performance
Financial StatementsNews
Harvard Apparatus Regenerative Technology Announces Strategic Collaboration with Children's Hospital Capital institute of Pediatrics in Beijing, China to Advance Treatment for Esophageal Atresia
Holliston, MA, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechn...
Harvard Apparatus Regenerative Technology Appoints Mao Zhang to Board of Directors
Holliston, MA, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechn...
Harvard Apparatus Regenerative Technology Announces $5 Million Financing to Continue Clinical Trial
Holliston, MA, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechn...
Harvard Apparatus Regenerative Technology Reports First Quarter 2024 Financial Results and Recent Business Highlights
Holliston, MA, May 13, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechno...
Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Holliston, MA, April 02, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotech...
Harvard Apparatus Regenerative Technology and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Establish a Research Collaboration to Study the Repair and Regeneration of the Colon following Colectomy
Holliston, MA, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechn...
Harvard Apparatus Regenerative Technology and Renowned Professor/Physician Establish a Collaboration to Repair and Regenerate the Uterus
Holliston, MA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechn...
Harvard Apparatus Regenerative Technology Reports Third Quarter 2023 Financial Results
Holliston, MA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechn...
Harvard Apparatus Regenerative Technology Schedules Conference Call and Webcast for Q3 2023 Results
HOLLISTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc . (OTCQB: HRGN) (“HRGN” or the “Company”), a clinical-stage biotechnology company developing the tec...
Activated University of Michigan as The Second Site for Clinical Trial in Severe Esophageal Disease
HOLLISTON, Mass. , Aug. 28, 2023 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) ("Harvard Apparatus Regenerative Technology" or the "Company"), a clinical-stage biotechn...
Approval of an Orphan Disease Application for its lead product, the Cellspan Esophageal Implant by the European Medicines Agency
HOLLISTON, Mass. , Aug. 21, 2023 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) ("Harvard Apparatus Regenerative Technology" or the "Company"), a clinical-stage biotechn...
Harvard Apparatus Regenerative Technology Reports Second Quarter 2023 Financial Results
HOLLISTON, Mass. , Aug. 14, 2023 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) ("Harvard Apparatus Regenerative Technology" or the "Company"), a clinical-stage biotechn...
Harvard Apparatus Regenerative Technology Schedules Conference Call and Webcast for Q2 2023 Results
HOLLISTON, Mass. , Aug. 9, 2023 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) ("HRGN" or the "Company"), a clinical-stage biotechnology company developing the technolog...
Biostage, Inc. Changes Name to Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN)
Name Change is Capstone of Corporate Rebranding Initiative for Regenerative Medicine ( www.hregen.com) - Trading Under OTCQB Symbol "HRGN" begins July 20, 2023 - HOLLISTON, Mass. , July 20, 2023 /PRN...